OCUP: Ocuphire Pharma, Inc. Stock

by  •  • Comments Off on OCUP: Ocuphire Pharma, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 52.89
Enterprise Value ($M) 5.72
Book Value ($M) 46.06
Book Value / Share 1.78
Price / Book 1.15
NCAV ($M) 46.06
NCAV / Share 1.78
Price / NCAV 1.15

Profitability (mra)
Return on Invested Capital (ROIC) -0.25
Return on Assets (ROA) -0.26
Return on Equity (ROE) -0.30

Liquidity (mrq)
Quick Ratio 8.96
Current Ratio 8.96

Balance Sheet (mrq) ($M)
Current Assets 51.84
Assets 51.84
Liabilities 5.79
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 19.05
Operating Income -10.56
Net Income -9.99
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -1.11
Cash from Investing 0.00
Cash from Financing 8.98

(click for more detail)
Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-05-10 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2024 ☐ TRANSITION REPORT PUR
2024-03-08 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K
2023-11-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2023 ☐ TRANSITION REPORT
2023-08-11 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2023 ☐ TRANSITION REPORT PURS

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-07-26 11,898 50,860 23.39
2024-07-25 15,686 103,601 15.14
2024-07-24 20,862 90,556 23.04
2024-07-23 21,557 127,494 16.91
2024-07-22 24,729 128,591 19.23

(click for more detail)

Similar Companies
NVCT – Nuvectis Pharma, Inc. OCEA – Ocean Biomedical, Inc.
OCGN – Ocugen, Inc. OCX – OncoCyte Corporation
OKYO – OKYO Pharma Limited


Financial data and stock pages provided by
Fintel.io